このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

アトピー性皮膚炎を有する3カ月から24カ月未満の参加者におけるタピナロフクリーム1%の安全性と有効性を検討する研究 (Adoring)

2026年11月6日 更新者:Organon and Co

タピナロフクリーム1%のアトピー性皮膚炎を有する生後3か月から24か月未満の小児参加者における安全性および有効性を調査するための、無作為化二重盲検ビヒクル対照(第1期間)およびオープンラベル(第2期間)第3相試験

The purpose of this global Phase 3 clinical study is to investigate the safety and efficacy of tapinarof cream, 1% in participants ages 3 months to 23 months (inclusive) with atopic dermatitis.

調査の概要

状態

積極的、募集していない

研究の種類

介入

入学 (実際)

187

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Alabama
      • Birmingham、Alabama、アメリカ、35209
        • AllerVie Clinical Research
    • Arkansas
      • Bryant、Arkansas、アメリカ、72022
        • Dermatology Trial Associates
    • California
      • Los Angeles、California、アメリカ、90045
        • Dermatology Research Associates
      • Sacramento、California、アメリカ、95815
        • Integrative Skin Science and Research
      • San Diego、California、アメリカ、92123
        • Allergy and Asthma Medical Group and Research Center
      • Thousand Oaks、California、アメリカ、91320
        • Clinical Trials Research Institute
    • Colorado
      • Castle Rock、Colorado、アメリカ、80109
        • Clarity Dermatology
    • Florida
      • Boca Raton、Florida、アメリカ、33486
        • Skin Care Research, LLC.
      • Jacksonville、Florida、アメリカ、32256
        • APEX Clinical Trials
      • Wellington、Florida、アメリカ、33449
        • TruDerm Research
    • Georgia
      • Cumming、Georgia、アメリカ、30040
        • Cleaver Medical Group Dermatology, Inc
    • Idaho
      • Meridian、Idaho、アメリカ、83646
        • Ada West Research
    • Illinois
      • Skokie、Illinois、アメリカ、60077
        • Endeavor Health Clinical Trials Center
    • Indiana
      • Indianapolis、Indiana、アメリカ、46250
        • Dawes Fretzin Clinical Research Group, LLC
      • Plainfield、Indiana、アメリカ、46168
        • The Indiana Clinical Trials Center, PC
    • Kentucky
      • Bowling Green、Kentucky、アメリカ、42104
        • Equity Medical, LLC
    • Maryland
      • Rockville、Maryland、アメリカ、20850
        • Lawrence J Green, MD LLC
    • Michigan
      • Auburn Hills、Michigan、アメリカ、48326
        • Oakland Hills Dermatology
    • Minnesota
      • New Brighton、Minnesota、アメリカ、55112
        • Minnesota Clinical Study Center
    • Mississippi
      • Ridgeland、Mississippi、アメリカ、39157
        • SKY Integrative Medical Center
    • Missouri
      • Saint Joseph、Missouri、アメリカ、64506
        • MediSearch Clinical Trials
    • Nevada
      • Reno、Nevada、アメリカ、89509
        • Skin Cancer and Dermatology Institute
    • New York
      • Kew Gardens、New York、アメリカ、11415
        • Forest Hills Dermatology Group
      • New York、New York、アメリカ、10012
        • Bobby Buka MD, PC
      • The Bronx、New York、アメリカ、10455
        • Equity Medical, LLC
    • North Carolina
      • Chapel Hill、North Carolina、アメリカ、27516
        • The University of North Carolina Dermatology and Skin Cancer Center
    • Ohio
      • Fairborn、Ohio、アメリカ、45324
        • Dermatologists of Central States, LLC
    • Oklahoma
      • Oklahoma City、Oklahoma、アメリカ、73120
        • Allergy Asthma and Clinical Research Center
    • Oregon
      • Portland、Oregon、アメリカ、97210
        • Oregon Dermatology and Research Center
      • Portland、Oregon、アメリカ、97239
        • Oregon Health & Science University
    • South Carolina
      • Charleston、South Carolina、アメリカ、29425
        • Medical University of South Carolina
      • North Charleston、South Carolina、アメリカ、29420
        • National Allergy and Asthma Research, LLC.
    • Texas
      • Bellaire、Texas、アメリカ、77401
        • The University of Texas Health Science Center at Houston
      • Dallas、Texas、アメリカ、75230
        • Dermatology Treatment and Research Center
      • Southlake、Texas、アメリカ、76092
        • Stryde Research - Epiphany Dermatology
    • Washington
      • Spokane、Washington、アメリカ、99202
        • Dermatology Specialists of Spokane
    • Alberta
      • Calgary、Alberta、カナダ、T2J 7E1
        • Dermatology Research Institute
      • Red Deer、Alberta、カナダ、T4P 1K4
        • CARe Clinic (Central Alberta Research Clinic)
    • British Columbia
      • Surrey、British Columbia、カナダ、V3R 6A7
        • Dr. Chih-Ho Hong Medical Inc.
    • Manitoba
      • Winnipeg、Manitoba、カナダ、R3J 0S9
        • Manitoba Allergy Research Inc.
    • Nova Scotia
      • Halifax、Nova Scotia、カナダ、B3K 5R3
        • Maritime Dermatology
    • Ontario
      • Burlington、Ontario、カナダ、L7L 6W6
        • Halton Pediatric Allergy
      • Hamilton、Ontario、カナダ、L8S 1G5
        • Triple A Lab Inc.
      • Niagara Falls、Ontario、カナダ、L2H 1C4
        • Allergy Research Canada Inc.
    • Saskatchewan
      • Regina、Saskatchewan、カナダ、S4V 1R9
        • Dr. Rachel Asiniwasis Medical Professional Corporation
      • Saskatoon、Saskatchewan、カナダ、S7K 2C1
        • Skinsense Medical Research

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

3ヶ月~1年 (子)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Infants and toddlers born at term (≥37 weeks of gestational age) that are 3 months to <24 months of age at the Screening visit.
  • Clinical diagnosis of atopic dermatitis (AD), AD covering >5% Body Surface Area (BSA) and validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of 2, 3 or 4
  • Legal guardian or primary caregiver is willing and able to sign informed consent form before any study-related activities
  • Legal guardian or primary caregiver is able and willing to adhere to protocol requirements

Exclusion Criteria:

  • Significant neurological disorder or history of seizure
  • Know clinically significant cardiac rhythm or cardiac disorder
  • History of sudden infant death in a sibling
  • Clinically significant chromosome abnormality
  • History of or ongoing serious illness or medical, physical or psychiatric condition(s) that may interfere with the participant's participation
  • Diseases that could cause pruritic and/or sleep disruption
  • Immunocompromised
  • Current chronic or acute infection requiring treatment
  • Use of prohibited medication(s) or procedure(s)
  • Use of prohibited medications by breastfeeding mother if breastfeeding participant

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
実験的:Tapinarof cream

Tapinarof cream, 1%, applied topically once daily

Tapinarof cream, 1%: Applied topically once daily to lesions on participant's skin during the Double-Blind period. During the Open-Label Period, it will be applied once daily to lesions, as needed.

他の名前:
  • DMVT-505
  • OG-0505
  • GSK2894512A
  • GSK28994512
  • STI-1001
  • WBI-1001
プラセボコンパレーター:Vehicle cream

Vehicle cream is applied topically once daily for up to 8-weeks.

Applied topically once daily to lesions on participant's skin during the Double-Blind period.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Percentage of participants who have a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of clear or almost clear (0 or 1) and a minimum 2-grade Improvement from Baseline to Week 8
時間枠:Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.

The vIGA-AD is a global assessment of the current state of the disease. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is reported as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease.

Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
Percentage of participants who enter with or achieve have a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of clear or almost clear (0 or 1) and a minimum 2-grade Improvement at least once during the Open-Label Period
時間枠:Baseline to the end of the Open-Label Period, up to 56 weeks.

The vIGA-AD is a clinical tool for assessing the current state/severity of a subject's atopic dermatitis at a given timepoint.. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is reported as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease.

Baseline to the end of the Open-Label Period, up to 56 weeks.

二次結果の測定

結果測定
メジャーの説明
時間枠
Percentage of participants with ≥ 75% improvement in Eczema Area and Severity Index (EASI) Score from Baseline to Week 8.
時間枠:Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.

The EASI is a scoring system that takes into account the overall severity of disease based on lesion severity and the %BSA affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. The subject's scalp is excluded from this assessment. A higher EASI score represents more severe disease.

Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
Mean change in percentage of total body surface area (%BSA) affected from Baseline to Week 8
時間枠:Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.

Assessment of %BSA is an estimate of the percentage of total involved skin with atopic dermatitis. Estimates were made using the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumbs together) represented approximately 1% of the total BSA. Body regions are assigned a specific number of handprints with associated percentages (Head and neck = 10% [10 handprints], upper extremities = 20% [20 handprints], trunk (including axillae and groin) = 30% [30 handprints], lower extremities, including buttocks, = 40% [40 handprints]). Estimates of the percent involvement of each body region will be multiplied by the fraction of total body area to obtain the total %BSA involved by region and overall.

Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
Percentage of participants with ≥ 90% improvement in Eczema Area and Severity Index (EASI) score from Baseline to Week 8
時間枠:Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.

Severity Index (EASI) score from Baseline to Week 8 Description: The EASI is a scoring system that takes into account the overall severity of disease based on lesion severity and the extent of percent body surface area affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the percent body surface area involved for each body region relative to the whole body. A higher EASI score represents more severe disease.

Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
Number of participants with one or more Treatment Emergent Adverse Events (TEAEs)
時間枠:Baseline to last planned visit in the Double-Blind Period, up to 8 weeks

TEAEs are AEs that started on or after the first dose of study medication.

Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
Number of participants with one or more Treatment Emergent Adverse Events (TEAEs)
時間枠:Baseline to the end of the Open-Label Period, up to 56 weeks

TEAEs are AEs that started on or after the first dose of study medication.

Baseline to the end of the Open-Label Period, up to 56 weeks
Percentage of participants with one or more Treatment Emergent Adverse Events (TEAEs)
時間枠:Baseline to last planned visit in the Double-Blind Period, up to 8 weeks .

TEAEs are AEs that started on or after the first dose of study medication.

Baseline to last planned visit in the Double-Blind Period, up to 8 weeks .
Percentage of participants with one or more Treatment Emergent Adverse Events (TEAEs)
時間枠:Baseline to the end of the Open-Label Period, up to 56 weeks.

TEAEs are AEs that started on or after the first dose of study medication.

Baseline to the end of the Open-Label Period, up to 56 weeks.
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (overall)
時間枠:Baseline to last planned visit in the Double-Blind Period, up to 8 weeks

The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation.

Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (overall)
時間枠:Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.

The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation.

Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (sensitive areas)
時間枠:Baseline to last planned visit in the Double-Blind Period, up to 8 weeks

The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation.

Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (sensitive areas)
時間枠:Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.

The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation.

Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Clinical Lead Late-Stage Clinical Development、Organon and Co

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年12月29日

一次修了 (推定)

2027年8月1日

研究の完了 (推定)

2027年8月1日

試験登録日

最初に提出

2025年11月21日

QC基準を満たした最初の提出物

2025年12月2日

最初の投稿 (実際)

2025年12月4日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月10日

QC基準を満たした最後の更新が送信されました

2026年11月6日

最終確認日

2026年8月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する